Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Prevention of Cancer Therapy Induced Bone Loss
NCT00375505Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zoledronic acid in osteoporosis, sponsored by Novartis. Started Oct 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00375505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00375505.